Acurx: Successful Completion and Early Discontinuation of Ibezapolstat Phase 2b Trial for C. dif

 

• Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as expected
• High rates of Clinical Cure were observed without any emerging safety concerns
• Data will be analyzed and topline efficacy results will be reported as soon as possible
• This successful milestone will allow advancement of this first-in-class, FDA QIDP/Fast Track-designated antibiotic candidate to Phase 3 clinical trials more expeditiously

https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-successful-completion-and-early-discontinuation-of-the-ibezapolstat-phase-2b-trial-for-treatment-of-c-difficile-infection-301943990.html